Home » Stocks » Biofrontera AG

Biofrontera AG (BFRA)

Stock Price: $7.50 USD -0.01 (-0.13%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
After-hours: $7.37 -0.13 (-1.73%) Oct 19, 6:24 PM

Stock Price Chart

Key Info

Market Cap 168.19M
Revenue (ttm) 35.13M
Net Income (ttm) -7.36M
Shares Out 22.42M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $7.50
Previous Close $7.51
Change ($) -0.01
Change (%) -0.13%
Day's Open 7.46
Day's Range 7.46 - 7.60
Day's Volume 28,617
52-Week Range 5.27 - 55.00

More Stats

Market Cap 168.19M
Enterprise Value 197.34M
Earnings Date (est) Nov 19, 2020
Ex-Dividend Date n/a
Shares Outstanding 22.42M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.76
FCF / Share -1.74
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 15,599
Short Ratio 0.01
Short % of Float n/a
Beta 1.42
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.79
PB Ratio 30.27
Revenue 35.13M
Operating Income -19.11M
Net Income -7.36M
Free Cash Flow -38.94M
Net Cash -29.15M
Net Cash / Share -1.30
Gross Margin 84.41%
Operating Margin -54.39%
Profit Margin -23.50%
FCF Margin -110.84%
ROA -11.79%
ROE -146.86%
ROIC -12.20%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(67.60% upside)
Current: $7.50
Target: 12.57
*Average 12-month USD price target from 3 stock analysts.

Financial Performance

Financial numbers in millions EUR.

Financial Overview

Revenue Growth48.13%75.53%96.17%48.14%-
Gross Profit26.3916.6610.314.482.90
Operating Income-17.01-17.51-15.01-9.38-10.23
Net Income-7.36-8.88-16.10-10.58-11.20
Shares Outstanding44.6344.24---
Earnings Per Share-0.32-0.40-0.84-0.72-0.96
Operating Cash Flow-32.89-13.43-13.12-10.26-9.66
Capital Expenditures-1.76-0.51-0.38-0.46-0.17
Free Cash Flow-34.66-13.95-13.50-10.72-9.82
Cash & Equivalents12.2020.2511.6515.804.69
Total Debt38.1413.6612.553.9312.10
Net Cash / Debt-25.956.59-0.8911.87-7.41
Book Value9.9616.363.3815.84-4.81
Numbers in millions EUR, except per-share numbers.

Company Profile

Company Details

Full Name Biofrontera AG
Country Germany
Employees 154
CEO Hermann Lübbert

Stock Information

Ticker Symbol BFRA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BFRA
IPO Date February 14, 2018


Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Company Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.